This is a Phase I, open-label, single-site trial to evaluate the drug release, using
scintigraphic images and mesalazine plasma levels (PK) in healthy subjects. Overall, nine [9]
subjects will be evaluated. The subjects will receive one [1] radio-labelled tablet after a
high fat and a rich in calories breakfast.